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Pulmonary hypertension (PH) is a serious disorder
that worsens the course of chronic heart, lung or
systemic diseases. However the need to discrimi-
nate PH, a pathophysiological condition, from pul-
monary arterial hypertension (PAH), which is a rare
clinical condition, has been recently stressed [1].
PH is defined as an increase in mean pulmonary ar-
terial pressure (PĀP) > 25 mm Hg at rest, as as-
sessed by right heart catheterisation. According to
various combinations of values of pulmonary capil-
lary wedge pressure (PCWP), pulmonary vascular
resistance (PVR) and cardiac output, different 
hemodynamic types of PH can be identified. In the
updated clinical classification of PH, 37 clinical
conditions with PH are classified into six groups ac-
cording to pathological, pathophysiological and
therapeutic characteristics: PAH (group 1), pul-
monary veno-occlusive disease (group 1’), PH due
to left heart disease (group 2), PH due to lung dis-
ease (group 3), chronic thromboembolic PH
(CTEPH, group 4) and PH with unclear and/or 
multifactorial mechanisms (group 5) [4].
In this issue of MRM, Bozbas et al. [2] report that
pulmonary hypertension is not uncommon in pa-
tients with end stage renal disease (ESRD). They de-
tected an increase of systolic pulmonary arterial
pressure (sPAP) in 85 of the 500 (17%) patients 
undergoing pre-transplant evaluation. Moreover, a
significant decrease was observed in mean sPAP
values in an average of 53 months of postoperative
follow up on 42 patients who had undergone both
pre- and post-transplant echocardiographic exami-
nation compared to pre-transplant values [3]. As the
authors acknowledge, their retrospective data have
the important limitation of lacking direct hemody-
namic assessment which would have readily diag-
nosed and classified PH occurring in ESRD.
Accordingly, the correlation between echocardio-
graphic estimate of sPAP and right heart catheteri-
zation is not absolute. Thus if we apply the PH echo
probability criteria of ESC/ERS guidelines [4], we
could find only 6 patients fulfilling PH high proba-
bility criteria. Nevertheless the potential role of PH
as a cardiovascular complication of ESRD should
be acknowledged.
The death rate among U.S patients undergoing dial-
ysis continues to exceed 20% per year during the
first 2 years after maintenance dialysis has begun.
Moreover, hospitalization rates have remained near-
ly constant, averaging almost 13 hospital days and
two admissions per patient/year [5]. It has been sug-
gested that dialysis-focused quality measures
should also include an assessment of risk factors for
cardiovascular disease which constitutes the major
cause of hospitalization and death in the population
receiving dialysis. Indeed while it is well known
that cardiovascular diseases including ischemic
heart disease, heart failure and arrhythmias are very
common and are the most frequent causes of mor-
tality in patients with ESRD, data on PH in patients
with ESRD are limited. 
PH is a strong independent predictor of mortality in
hemodialysis (HD) patients [6]. In a recent review,
the prevalence of PH in ESRD patients was reported
to be around 40-50% [7]. Its frequency has been re-
ported to be higher in HD than in peritoneal dialy-
sis (PD) patients due to the presence of arterio-ve-
nous fistula (AVF) [8]. The mechanisms involved in
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PH development are still under investigation, but it
has been reported that HD patients with PH show a
significantly higher cardiac output than HD patients
with normal sPAP [9]. It has been suggested that
some factors such as the size or the location of AVF
are involved in the mechanism that increases PAP,
as an AVF with a high flow may have a flow of 1.0–
1.5 L/min with a cardiopulmonary recirculation up
to 20% [10,11]. 
It has been reported that PH improves after success-
ful kidney transplantation, as well as after short AVF
compression, indicating that both ESRD and AVF
contribute to its pathogenesis [12]. Issa et al. report-
ed that time on dialysis was the strongest correla-
tion to elevated right ventricular systolic pressure.
The same authors stated that right ventricular sys-
tolic pressure greater than 50 mm Hg was associat-
ed with significant reduced post-transplant survival
[12]. Interestingly, data from the REVEAL Registry
[13], which has collected a large number of PAH
patients, show that 10% of these patients demon-
strate PCWP between 15 and 18 mm Hg depicting
a grey zone of unclear clinical significance.
Remarkably, obesity, sleep apnea and renal failure
were among the factors responsible for PCWP in-
crease while left heart echo data did not differ in
comparison to patients with PAH and PCWP < 
15 mm Hg, suggesting that chronic renal disease
could potentially represent an aggravating factor al-
so in PAH.
There is much debate on the occurrence of severe
PH, with clinical characteristics resembling idio-
pathic PH, in groups other than PAH. Actually in
both groups 2 and 3 (e.g. left heart disease and lung
disease, respectively) patients with severe out-of-
proportion PH have been identified, raising the
question of a possible targeted therapy for these pa-
tients [4]. From this point of view there is evidence
that endothelial dysfunction may play a role in 
ESRD patients interfering with a possible target of
the drugs used in PAP. Patients with chronic renal
failure (CRF) show an endothelial dysfunction relat-
ed to defective nitric oxide activity, which is not
corrected by hemodialysis (HD). Nakhoul et al. [11]
demonstrated that reduced nitric oxide production
could increase PAP; furthermore, PH among HD
patients who underwent successful kidney trans-
plantation reversed, even if their AVF remained
patent. Moreover, HD induces a detectable extra-
corporeal increase of thromboxane(TX)B2, through
blood membrane interaction causing degranulation
of neutrophils with the increase of TXB2 in HD pa-
tients. The increased synthesis of these vasoactive
agents may lead to pulmonary venous constriction,
as pulmonary veins are the primary sites of action of
thromboxane, with increased microvascular pres-
sures and abnormalities in gas exchange leading to
hypoxia and consequent pulmonary vasoconstric-
tion (14). Other risk factors for PH associated to 
ESRD have been identified such as age and hor-
monal disturbances. Hyperparathyroidism, by caus-
ing precipitation of calcium in many tissues, could
play a role in the development of PH secondary to
pulmonary artery, but other studies did not confirm
this finding in ESRD on regular HD [15,16]. Finally
diastolic dysfunction may contribute to the devel-
opment of PH by causing an elevated left atrial
pressure. Accordingly, patients with brachial AVF
have a more than double risk of developing PH,
while patients with left ventricular diastolic dys-
function (LVDD) have a very high risk compared to
those without LVDD [17,18]. To summarize the oc-
currence of pulmonary hypertension is likely to be
multifactorial (see Table I).
In conclusion, the data of Bozbas et al. are wel-
come because they unmask the clinical problem of
PH in ESRD, which may represent a challenge for
many medical specialties in the future. It is likely
that the application of current guidelines and diag-
nostic algorithms in this patient population will in-
crease our knowledge concerning the true rele-
vance of kidney pulmonary hypertension.
TABLE I: CONFIRMED AND SUSPECTED FACTORS LEADING
TO INCREASED SYSTOLIC PULMONARY ARTERIAL PRESSURE
IN END STAGE RENAL DISEASE (ESRD)
Factors of PH in ESRD Consequences 
High flow arteriovenous fistula High cardiac output
Endothelium dysfunction ↓NO;   ↑TXB;  ↑ET-1
Left heart dysfunction ↑pulmonary wedge pressure 
Hormonal disturbances Hyperparathyroidism
Abnormal gas exchange Hypoxia, pulmonary vasoconstriction                            
Definition of abbreviations: ET, endothelin; PH, pulmonary hyperten-
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